Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer (Q39340402)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 May 2012

Language	Label	Description	Also known as
English	Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer	scientific article published on 27 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Listeria monocytogenes

0 references

adaptive radiation therapy

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Raquibul Hannan

object named as

Raquibul Hannan

1

0 references

author name string

Huagang Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Anu Wallecha

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Reshma Singh

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Laibin Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Patrice Cohen

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Alan Alfieri

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

John Rothman

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Chandan Guha

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

27 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

61

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2227-2238

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Current vaccination strategies for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Combining radiotherapy and immunotherapy: a revived partnership

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Irradiated pancreatic cancer cells undergo both apoptosis and necrosis, and could be phagocytized by dendritic cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Cellular responses to interferon-gamma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Immunotherapy and prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Development of a Listeria monocytogenes based vaccine against prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Successful combination of local CpG-ODN and radiotherapy in malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Is alpha/beta for prostate tumors really low?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1257-X

21 January 2018

Identifiers

10.1007/S00262-012-1257-X

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39340402&oldid=2202792613"